DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of DS3201 when given together with
and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer
that has spread to other places in the body (metastatic). DS3201 may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving DS3201 and ipilimumab
may help to control the disease.